tacrolimus and Cheilitis

Topics: Administration, Topical; Adult; Biopsy; Cheilitis; Drug Therapy, Combination; Female; Hashimoto Disease; Humans; Immunosuppressive Agents; Male; Psoriasis; Recurrence; Salicylic Acid; Tacrolimus; Young Adult

Tacrolimus is a new type immunosuppressant. The aim of this study was to evaluate the effectiveness of topical tacrolimus 0.1% ointment at 2 different frequencies in treating patients with exfoliative cheilitis.. A total of 40 patients with exfoliative cheilitis were randomly divided into the QD group receiving topical tacrolimus 0.1% ointment once a day or the QOD group receiving topical tacrolimus 0.1% ointment once-two-day. Patients were also applied wet dressing of saline twice a day. The effectiveness of treatment was defined as the percentage of improvement in signs or symptoms.. 37 patients completed the 2-week treatment. And, a full set was analyzed. The effectiveness of topical tacrolimus 0.1% ointment for relief in objective sign and subjective symptom was 50% and 67.5%% in the QD group, respectively. For the QOD group, the effectiveness of sign and symptom relief was 50% and 73.5%. There was no significant difference of effectiveness between application topical tacrolimus once a day and once 2 days.. Our data suggested that application of topical tacrolimus 0.1% ointment once a day and once 2 days had similar clinical effectiveness for sign and symptom relief in patients with exfoliative cheilitis.

Topics: Administration, Topical; Cheilitis; Humans; Immunosuppressive Agents; Ointments; Pilot Projects; Tacrolimus; Treatment Outcome

Tacrolimus has been used to treat various inflammatory skin diseases, but its safety for topical application on the oral mucosa is unknown. Exfoliative cheilitis (EC) is a chronic inflammatory disorder of the lips characterised by repeated scaling; it is difficult to manage. The aim of this study was to assess the efficacy and safety of tacrolimus 0.03% ointment as a topical treatment in patients with EC.. In this randomised controlled clinical trial, 40 patients with EC were randomly assigned to receive either tacrolimus 0.03% ointment (experimental group, n = 20) or triamcinolone acetonide 0.1% cream (control group, n = 20) treatment for a 3-week period. Medication was administered in 3, 2 and 1 daily doses during the first, second and third weeks, respectively. The patients with complete healing were followed up for 3 months. The clinical outcomes were measured, including the scores regarding signs (scale, dryness, rhagades and swelling) and symptoms (rough, dry, pain, pruritus and burning sensation) at every visit. Blood concentrations of tacrolimus were assessed.. After the 3-week treatment, healing rates of scale in the experimental and control groups were 65% and 10%, respectively (P = .018). Improvement in all signs and two symptoms (rough, pruritus) was much greater in the experimental group (P < .05). The 3-month recurrence rate was higher in the control group (P = .029). Tacrolimus blood concentrations were in the safe range (< 5 ng/mL).. Topical tacrolimus 0.03% ointment has good short-term efficacy and safety for treating EC.

Topics: Administration, Topical; Cheilitis; Humans; Immunosuppressive Agents; Ointments; Tacrolimus; Treatment Outcome

To assess the prevalence of oral manifestations in a group of allogenic liver, kidney or haematopoietic stem cell transplantation recipients and patients, and analyze the possible oral manifestations associated with the use of 4 immunosuppressive drugs.. One hundred and eighteen patients submitted to liver, kidney and hematopoietic stem cell transplantation who used tacrolimus， sirolimus，cyclosporine or mycophenolate mofetil were enrolled. Through a questionnaire survey and oral examination, their oral manifestations were recorded, and the possible statistical associations with immunosuppressive drugs were analyzed using SPSS 21.0 software package.. The prevalence of oral lichenoid lesions and cheilitis for the group of patients using tacrolimus after transplantation was significantly lower than the group of patients who did not used the agent(P＜0.01). The prevalence of oral lichenoid lesions for the group of patients who used cyclosporine was significantly higher than the group of patients who did not used the drug(P＜0.05), and the prevalence of cheilitis for the group of patients who used cyclosporine was significantly higher than the group of patients who did not used the drug(P＜0.01). The prevalence of oral lichenoid lesions and cheilitis for the group of patients who used tacrolimus was significantly lower than the group of patients who used cyclosporine(P＜0.01). The group of patients who used mycophenolate mofetil after transplantation had a significantly lower prevalence of dry mouth than the group of patients who did not used the drug(P＜0.01). The prevalence of oral manifestations in patients with sirolimus after transplantation was not significantly reduced.. The use of tacrolimus improved the symptoms of oral lichenoid lesions and cheilitis and the effect was better than cyclosporine after transplantation. The use of mycophenolate mofetil improved dry mouth after organ transplantation.

Topics: Cheilitis; Cyclosporine; Humans; Immunosuppressive Agents; Mycophenolic Acid; Organ Transplantation; Sirolimus; Tacrolimus; Xerostomia

Topics: Cheilitis; Humans; Immunosuppressive Agents; Minocycline; Psychotherapy; Tacrolimus

Exfoliative and erosive cheilitis, may be a source of speech and chewing discomfort, but may also be an aesthetic issue for the patients affected. Such a clinical presentation may implicate a variety of inflammatory conditions, including atopic (eczematous) cheilitis. Topical and systemic agents, e.g. corticosteroids, have been used to treat inflammatory lip conditions. Topical tacrolimus has also been used in some inflammatory lip conditions.. We performed a retrospective clinical analysis of atopic cheilitis patients.. Between 2015 and 2020, we addressed 7 (seven) patients with atopic dermatitis affecting only lips and were diagnosed as atopic-eczematous cheilitis. They were treated with 0.03 per cent topical tacrolimus ointment and responded completely.. These cases represent an underreported atopy / eczema event;-few cases of atopic cheilitis without concomitant dermal lesions appear in the literature. We are also showing and discussing yet another application of tacrolimus in a local atopic form of inflammation affecting the lips.

Topics: Administration, Topical; Cheilitis; Esthetics, Dental; Humans; Immunosuppressive Agents; Lip; Retrospective Studies; Tacrolimus; Treatment Outcome

Topics: Administration, Topical; Calcineurin Inhibitors; Cheilitis; Humans; Male; Middle Aged; Ointments; Plasma Cells; Tacrolimus

Plasma cell cheilitis is an extremely rare disease, characterized by erythematous-violaceous, ulcerated and asymptomatic plaques, which evolve slowly. The histological characteristics include dermal infiltrate composed of mature plasmocytes. We report a case of Plasma cell angular cheilitis in a 58-year-old male, localized in the lateral oral commissure.

Topics: Cheilitis; Humans; Immunosuppressive Agents; Lymphocytes; Male; Middle Aged; Neutrophil Infiltration; Plasma Cells; Tacrolimus

Plasma cell cheilitis is a chronic inflammatory disease that presents with erythema, erosions, ulcers and occasional nodules within the mucosa, including the lips. It is histopathologically characterized by dense plasma cell infiltration in the lamina propria of the mucous membranes. Several treatments for plasma cell cheilitis have been reported, including topical steroids, topical antibiotics or topical tacrolimus. However, 308-nm monochromatic excimer light (MEL) has never been reported as a treatment option, while it was reported to be very effective in treating erosive oral lichen planus. We report a 62-year-old man who had chronic plasma cell cheilitis on the lower lip, which was refractory to topical and systemic corticosteroid. The lesion and severe pain were significantly improved by the treatment with nine sessions of 308-nm MEL twice per week with a total dose of 1120 mJ/cm(2). However, the lesion gradually worsened after treatment frequency was reduced to once per month. Subsequent tacrolimus 0.03% ointment cleared the lesion completely in a month and no recurrence was observed a year later. Refractory plasma cell cheilitis and concomitant severe pain quickly responded to 308-nm MEL when administrated twice per week. Because the long interval between each MEL treatment seemed ineffective to improve the lesion, appropriate frequency and adequate total dose of MEL treatment may be necessary for a successful treatment.

Topics: Cheilitis; Humans; Immunosuppressive Agents; Lasers, Excimer; Lip; Male; Middle Aged; Plasma Cells; Tacrolimus

Exfoliative cheilitis (EC) is a rare inflammatory condition affecting the vermilion of the lips and characterized by production of a thick keratin scale. Given the limited available data, the approach to optimal management of EC remains unclear. The objective of this retrospective study was to characterize the clinical features, management, and outcomes of a series of patients with EC. Fifteen patients with a median age of 59 years and a female-to-male ratio of 2:1 were diagnosed with EC from 2000 to 2010. Parafunctional lip licking (53%) and a history of psychiatric disorders (40%) were common. Ten patients (66%) returned for follow-up, with an overall response rate (partial or complete) of 80% at a median of 2 months, most frequently associated with the use of topical calcineurin inhibitors or moisturizing agents. Management of EC with topical calcineurin inhibitors and moisturizing agents is associated with clinical improvement, but prospective trials are needed.

Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Biopsy; Cheilitis; Dermatologic Agents; Emollients; Female; Humans; Keratolytic Agents; Male; Middle Aged; Mupirocin; Petrolatum; Photomicrography; Retrospective Studies; Tacrolimus; Tretinoin

Plasma cell cheilitis is an uncommon chronic inflammatory dermatitis that presents with flat to slightly elevated erosive erythematous plaques. It is histologically characterized by plasma cell infiltrates into the mucosa. Other than the lip, genital areas are often involved, which is called plasma cell balanitis or vulvitis. Plasma cell cheilitis is sometimes resistant to conventional topical corticosteroid therapy. Other choices include oral griseofulvin, topical cyclosporine, and intralesional corticosteroid injection, all of which occasionally fail to produce satisfactory results. Recent reports show that topical calcineurin inhibitors are effective for plasma cell cheilitis, balanitis, and vulvitis. However, there are so far only 2 reports of plasma cell cheilitis successfully treated with topical pimecrolimus and tacrolimus. We present herein two cases of plasma cell cheilitis, in which topical tacrolimus showed beneficial effects, suggesting that this immunomodulatory agent is a promising option for plasma cell cheilitis.

Topics: Administration, Topical; Aged; Cheilitis; Humans; Immunosuppressive Agents; Male; Plasma Cells; Tacrolimus

Plasma cell cheilitis is a rare, idiopathic mucosal condition. The treatment of plasma cell cheilitis is often disappointing. It is often resistant to various topical treatments. We present a 65-year-old woman who had a painful, eroded area on her lower lip, which responded poorly to various topical treatments. A biopsy revealed a band-like infiltration composed mainly of plasma cells in the dermis. She was diagnosed as having plasma cell cheilitis, and was successfully treated with 0.03% topical tacrolimus ointment.

Topics: Administration, Topical; Aged; Biopsy, Needle; Cheilitis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Ointments; Plasma Cells; Tacrolimus; Treatment Outcome

Topics: Administration, Oral; Anti-Bacterial Agents; Cheilitis; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Middle Aged; Minocycline; Ointments; Tacrolimus

Topics: Administration, Topical; Aged; Calcineurin Inhibitors; Cheilitis; Female; Humans; Immunosuppressive Agents; Male; Plasma Cells; Tacrolimus

Ethylene glycol is a colorless, odorless, nonvolatile, water-soluble fluid, mainly used as automobile antifreeze and coolant. This substance is a frequent culprit in accidental and intentional poisonings. Although potentially fatal systemic consequences of ethylene glycol ingestion are well known, local adverse effects through brief skin and mucosa contact with ethylene glycol have been rarely reported. Herein we report a patient with accidental ethylene glycol contact to the lower lip, who presented with acute, manifest, actinic cheilitis-like chemical irritant reaction and favorably responded to topical pimecrolimus 1% cream.

Topics: Accidents; Administration, Topical; Cheilitis; Ethylene Glycol; Humans; Immunosuppressive Agents; Lip; Male; Middle Aged; Mouth Mucosa; Tacrolimus

Topics: Administration, Topical; Adult; Cheilitis; Humans; Immunosuppressive Agents; Lichen Planus, Oral; Male; Palliative Care; Salivary Gland Diseases; Tacrolimus

Topics: Administration, Topical; Adult; Cheilitis; Female; Humans; Immunosuppressive Agents; Tacrolimus